Source: globenewswire.com
Novartis has received an approval from the US FDA for its drug, Egaten (triclabendazole). Egaten is used for the treatment of fascioliasis in patients six years of age and older, and is currently the only FDA-approved drug for people with this disease. Fascioliasis also known as liver fluke infestation is a neglected tropical disease that infects 2.4 million people worldwide, with an additional 180 million at risk of infection. It is caused by two species of parasitic flatworms that can infect humans following ingestion of larvae in contaminated water or food. Egaten is currently the only medicine for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines.
